Clinical Trial Update: Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating sorafenib in combination with zoledronic acid for advanced hepatocellular carcinoma, sponsored by Fudan University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Zometa (Zoledronic acid)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN